drugset / Trial / NCT03460678

Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.

NCT03460678

Phase 4 Terminated 9 enrolled Hikma Pharmaceuticals LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this multicenter randomized study is to compare the effectiveness and safety of erlotinib and pemetrexed in the maintenance treatment of patients with advanced non-squamous non-small cell lung cancer (NSCLC)

Timeline

Start
2018-02-28
Primary completion
2018-11-14
Completion
2018-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule 150 mg Oral
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous